戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ment of refractory detrusor overactivity and overactive bladder.
2 ) agonist approved only for the treatment of overactive bladder.
3  involved in the management of patients with overactive bladder.
4 ecent developments in pharmacotherapy of the overactive bladder.
5 ted pig bladder strips, an in vitro model of overactive bladder.
6 evere lower urinary tract symptoms including overactive bladder.
7 and are obvious targets for treatment of the overactive bladder.
8 openers may have utility in the treatment of overactive bladder.
9 sorders of urine storage and voiding such as overactive bladder.
10  bladder compliance, ultimately resulting in overactive bladder.
11  to the pathophysiology of endometriosis and overactive bladder.
12 nd identify TRPV4 up-regulation in aging and overactive bladders.
13                                              Overactive bladder affects 10-12% of men, of which 13% a
14                                              Overactive bladder affects 10-27% of men, a significant
15 on is required to identify the true cause of overactive bladder, allowing new targeted treatments to
16 -five urine specimens (from 41 patients with overactive bladder and 24 controls) were examined using
17 drugs remain the first-line treatment of the overactive bladder and a favorable efficacy/tolerability
18  dysfunctional voiding, Botox injections for overactive bladder and an adult anticholinergic for over
19                                              Overactive bladder and benign prostatic hyperplasia comm
20                Control patients did not have overactive bladder and did not have a clinically relevan
21 ents for common urological disorders such as overactive bladder and interstitial cystitis/bladder pai
22 on may provide a novel approach for treating overactive bladder and interstitial cystitis/bladder pai
23 cantly less likely to receive a diagnosis of overactive bladder and more likely to receive a diagnosi
24                                     Men with overactive bladder and other lower urinary tract symptom
25 nation with an alpha-blocker, in men with an overactive bladder and summarize the efficacy and safety
26 d clinical trials, to establish the cause of overactive bladder and to determine the best method of m
27 ndicate that BK channel dysfunction leads to overactive bladder and urinary incontinence.
28 ure drug targets for effective management of overactive bladder are discussed.
29 ry to benign prostatic hyperplasia (BPH), an overactive bladder detrusor (a syndrome of urinary urgen
30                                Treatment for overactive bladder detrusor muscle, including anticholin
31 mon among men and are usually caused by BPH, overactive bladder detrusor, or both.
32  may be a viable target for the treatment of overactive bladder disorders.
33  from urothelium results in incontinence and overactive bladder due to abnormal mechanotransduction;
34                                              Overactive bladders exhibited greater TRPV4-induced ATP
35 ere are persistent urinary storage symptoms (overactive bladder) following therapy with an alpha-bloc
36     New theories and modified definitions of overactive bladder have been proposed, structured eviden
37                       Present treatments for overactive bladders have significant non-compliance rate
38 r existing anticholinergics, in treating the overactive bladder in children need closer scrutiny.
39 l nerve neuromodulation for the treatment of overactive bladder in patients who do not respond to opt
40                                          The overactive bladder is a common and distressing condition
41                                              Overactive bladder is a common problem affecting women w
42                                              Overactive bladder is an important lower urinary tract s
43                                              Overactive bladder is now recognized as a chronic debili
44 ur understanding of the basic science of the overactive bladder it is becoming clear that the control
45                          However, coexisting overactive bladder may be responsible for storage sympto
46         Anticholinergic medications to treat overactive bladder (OAB) have been associated with incre
47                                              Overactive bladder (OAB) is a highly prevalent symptom c
48                                           As overactive bladder (OAB) is a prevalent and chronic medi
49                                              Overactive bladder (OAB) is often treated with medicatio
50                                              Overactive bladder (OAB) symptoms in Parkinson disease (
51  human beta3-AR agonist for the treatment of overactive bladder (OAB), is described.
52 tor agonists (beta3-AR) for the treatment of overactive bladder (OAB).
53 ld be an effective therapy for patients with overactive bladder (OAB); however, this approach is cont
54 al treatment of men with incontinence due to overactive bladder or to stress urinary incontinence pub
55                     In women with refractory overactive bladder or urgency predominant mixed urinary
56 Women aged 18 years or older with refractory overactive bladder or urgency predominant mixed urinary
57 veral potential targets for treatment of the overactive bladder, particularly within the mechanosenso
58 on the Urogenital Distress Inventory and the Overactive Bladder Questionnaire (both P <0.001) at both
59 both before and after RTx as measured by the Overactive Bladder Questionnaire and International Prost
60 nd 2010 were asked to complete the validated Overactive Bladder Questionnaire based on patient sympto
61 oCA score (1.3 points vs. 0.3 points) or the Overactive Bladder Questionnaire score (-3.3 points vs.
62  lower scores indicate worse cognition), and Overactive Bladder Questionnaire score (range, 0 to 100;
63 inumtoxinA showed greater improvement in the Overactive Bladder Questionnaire SF for symptom bother (
64 om baseline in urinary symptom scores in the Overactive Bladder Questionnaire Short Form (SF); range,
65 ynamic cystometry in conscious mice revealed overactive bladder, reduced maximal voiding pressures an
66 00, higher scores indicating worse symptoms; Overactive Bladder Satisfaction questionnaire; range, 0-
67 ement, urinary retention, and underactive or overactive bladder.SIGNIFICANCE STATEMENT The pontine mi
68 dies using anticholinergics in patients with overactive bladders supports these findings.
69 rusor instability with subsequent obstructed/overactive bladder symptom complexes not dissimilar to t
70 y, inhibit detrusor overactivity and resolve overactive bladder symptoms acutely.
71 g that prostatic inflammation contributes to overactive bladder symptoms in male patients; however, l
72       Men with enlarged prostates experience overactive bladder symptoms of urgency and frequency.
73 hat in men with persistent storage symptoms (overactive bladder symptoms), clinically meaningful impr
74 ht be useful clinically for the treatment of overactive bladder symptoms.
75 y in the management of women with refractory overactive bladder symptoms.
76  cystitis/bladder pain syndrome (IC/BPS) and overactive bladder syndrome (OAB) are incompletely under
77 ection and a control group the prevalence of overactive bladder syndrome (OAB), and how it was associ
78 lay a significant role in the development of overactive bladder syndrome (OAB).
79        Lower urinary tract disorders such as overactive bladder syndrome (OABS) and interstitial cyst
80                                              Overactive bladder syndrome (OBS) results from disturban
81 current study was to assess the frequency of overactive bladder syndrome (OBS) symptoms and their rel
82  gastroesophageal reflux disease (GERD), and overactive bladder syndrome (OBS), as well as other gast
83 apy of lower urinary tract disorders such as overactive bladder syndrome and cystitis.
84 ctive pilot study including 15 patients with overactive bladder syndrome and five controls.
85 ower urinary tract storage disorders such as overactive bladder syndrome and urinary incontinence sig
86  link between the urethral virome and female overactive bladder syndrome, and by aligning these findi
87  lower urinary tract symptoms, including the overactive bladder syndrome, and that combination of the
88 tment of nonobstructed urinary retention and overactive bladder syndrome, especially when accompanied
89  treatment of obstructive airway disease and overactive bladder syndrome.
90 ifenacin, as a treatment alternative of male overactive bladder syndrome.
91 he treatment of lower urinary tract symptoms/overactive bladder syndrome/and detrusor overactivity.
92 ive bladder and an adult anticholinergic for overactive bladder that underwent testing in children; e
93 tion and therefore are candidate targets for overactive bladder therapy.
94 oms and nonobstructive pattern recognized as overactive bladder type has also been successfully evalu
95 actions is pivotal to the disease process in overactive bladder, urge incontinence, and spinal cord i
96 example is sacral nerve stimulation to treat overactive bladder, urinary incontinence and interstitia
97 bo effects across different diseases such as overactive bladder, urinary incontinence, lower urinary
98                    Treatment options for the overactive bladder were recently discussed at the 4th In
99                      This mix of obstructed, overactive bladder with hidden stress incontinence incre